In the preceding video, Fool.com analyst David Williamson discusses today's three top movers in the health-care sector. First up is Threshold Pharmaceuticals, down 12% as it appears likely to come in second to Celgene (CELG)in the race to move competing pancreatic cancer drugs through phase 3 trials. Peregrine is another pharma in freefall, with shares down another 17% after already having lost 80% of its value in September. Finally, on the receiving end of some good news in this space is Novavax(NVAX -9.65%), up 8% today on no specific news, and up 35% YTD.
One recent success story in the do-or-die biotech industry is Arena Pharmaceuticals. After gaining FDA approval for its innovative obesity drug, the future is looking bright, although there are still plenty of obstacles ahead for the company. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of free updates for those who sign up. To learn more and access your report today, click here now.
